Literature DB >> 30738446

[Expression and Clinical Significance of STAT3 Genes in Patients with Acute Myeloid Leukemia].

Cheng-Shuang Huang1, Mei Tan1, Xiang-Mei Zhang1, Xi Luo1, Run-Mei Tian1, Qiong Su1, Liu-Song Wu1, Yan Chen2.   

Abstract

OBJECTIVE: To investigate the expression of STAT3 gene in patients with acute myeloid leukemia and its correlation with clinical characteristics.
METHODS: The real-time quantitative RT-PCR was used to detect the level of STAT3 mRNA in bone marrow samples from 38 newly diagnosed patients with acute myeloid leukemia(AML), and its relevance with clinical characteristics and prognosis were statistically analyzed. Western blot was employed to detect the STAT3 protein level in AML patients. The bone marrow cells from 15 healthy subjects were used as control.
RESULTS: At the mRNA level, the expression level of STAT3 in the AML group was significantly higher than that in control group (P<0.05). The level of STAT3 in AML group correlated positively with the risk factors of patients (P<0.01,r=0.592). The STAT3 expression level in the high-risk group was statistically higher than that in the standard-risk group and the control group (P<0.01,P<0.01). Furthermor, there was no statistical difference between the sub-groups of AML (P>0.05). The median survival time of patients in STAT3 low expression group was logner than that in high expression group, but the difference was not statistically significant (P>0.005). The level of STAT3 protein in AML patients was significantly higher than that in control group (P<0.05).
CONCLUSION: The STAT3 gene is highly expressed in AML patients, which may be used as a predictor for high-risk of AML.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30738446     DOI: 10.7534/j.issn.1009-2137.2019.01.008

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  1 in total

1.  HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.

Authors:  İlayda Alcitepe; Hilal Salcin; İlknur Karatekin; Burcin Tezcanli Kaymaz
Journal:  Med Oncol       Date:  2022-10-12       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.